Therapeutic Asset Ratings
251 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Ethiodized Oil
Narrow Margin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P3
B
(60)
Ethiodized Oil
Radiotherapy, Adjuvant
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P3
B
(60)
Theprubicin
Immune Checkpoint Inhibitor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P3
B
(60)
Theprubicin
Narrow Margin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P3
B
(60)
Theprubicin
Radiotherapy, Adjuvant
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P3
B
(60)
Adebrelimab
HR Positive/HER2 Low Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(60)
Vinorelbine
Brain Metastases
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(60)
Mitoxantrone
Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P3
B
(59)
Fluzoparib
Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(59)
Mitoxantrone
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P3
B
(58)
Cyclophosphamide
Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(58)
Romiplostim
Chemotherapy-Induced Thrombocytopenia
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(58)
Tucidinostat
Chemotherapy Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(58)
Capecitabine
Rectal Diseases
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(57)
Eloxatin
Oxaliplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(57)
Eloxatin
Rectal Diseases
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(57)
FLUOROURACILUM
Oxaliplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(57)
Pyrotinib
Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(57)
rc48-adc
Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(57)
Tislelizumab
Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(57)
Pyrotinib
Pyrotinib Treatment
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2/3
B
(57)
Romiplostim
Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
B
(56)
Cyclophosphamide
Neuroendocrine Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
CCC
(55)
Epirubicin
Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
CCC
(55)
Fludarabine
Neuroendocrine Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
CCC
(55)
Showing 26 to 50 of 251 assets
Previous
Page 2 of 11
Next